



**William S. Lawrence, PhD**  
Assistant Professor, Microbiology & Immunology  
Director, Aerobiology Division  
301 University Blvd  
Galveston, Texas 77555-0610  
O 409.266.6919 F 409.266.6910  
E [wslawren@utmb.edu](mailto:wslawren@utmb.edu)  
W.[microbiology.utmb.edu/faculty/William-s-lawrence-phd](http://microbiology.utmb.edu/faculty/William-s-lawrence-phd)

Jeffrey Mullen  
Chief Executive Officer  
Dynamics Inc.  
493 Nixon Road  
Cheswick, PA 15024

Dear Mr. Mullen:

My laboratory is located in the Galveston National Laboratory at the University of Texas Medical Branch, a facility constructed with funds from the National Institute of Health, National Institute of Allergy and Infectious Disease.

On September 25, 2020, we tested the Nanowave device developed by Dynamics Inc. to measure inactivation of aerosolized SARS-CoV-2. SARS-CoV-2 (WA-01 isolate) was aerosolized and moved through the Nanowave device at the maximum airflow capability of our laboratory. Virus was inactivated at the maximum airflow to the detection limits of the test. Details of the SARS-CoV-2 inactivation test are attached hereto as Appendix A.

Sincerely,

A handwritten signature in cursive script that reads "William Lawrence".

William S. Lawrence, Ph.D.  
Assistant Professor, Microbiology & Immunology  
Director, Aerobiology Division  
University of Texas Medical Branch  
Galveston, TX 77555-0610

## APPENDIX A

### SARS-CoV-2 Inactivation With Dynamics Inc. Nanowave Technology

| Test                               | Test Duration | Nebulizer | Biosampler 1 (Before Device) | Biosampler 2 (After Device) | Average Humidity |
|------------------------------------|---------------|-----------|------------------------------|-----------------------------|------------------|
| Nanowave device at 20 LPM when ON  | 10 min        | 2.5E+07   | 2.5+04                       | <50                         | 86.71%           |
| Nanowave device at 30 LPM when ON  | 10 min        | 2.5E+07   | NA                           | <50                         | 84.67%           |
| Nanowave device at 20 LPM when OFF | 10 min        | 2.5E+07   | 7.5E+04                      | 7.5E+04                     | 84.93%           |
| Nanowave device at 30 LPM when OFF | 10 min        | 5.0E+07   | NA                           | 7.5E+04                     | 85.64%           |

#### Test Notes

- SARS-CoV-2 virus utilized was WA01 Strain.
- Biosampler 1 was placed before the Nanowave Device and is the control sample.
- Biosampler 2 was placed after the Nanowave Device.
- To achieve 30LPM, biosampler 1 was removed. Result was determined based on other correlated data.
- Values provided as Median Tissue Culture Infectious Dose / ml (TCID50/ml).
- Humidity was not controlled but was sampled 121 times during each test.